首頁 > 市場調查報告書 > 製藥

自體免疫疾病

市場調查報告書

商品編碼

1800307

全球抗風濕藥物市場：未來預測（2025-2030）

Global Anti-Rheumatic Drug Market - Forecasts fom 2025 to 2030

出版日期: 2025年08月15日 | 出版商:

Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

抗風濕藥物市場預計將從 2025 年的 744.44 億美元成長到 2030 年的 842 億美元，複合年成長率為 2.49%。

由於風濕病（尤其是類風濕性關節炎(RA)）盛行率不斷上升以及人口老化，抗風濕藥物市場正在經歷顯著成長。這些慢性疾病，包括 RA、乾癬性關節炎、紅斑性狼瘡和骨關節炎，會引起關節、肌肉和骨骼的發炎、疼痛和僵硬，嚴重影響患者的生活品質。抗風濕藥物，包括非類固醇消炎劑(NSAID)、皮質類固醇、緩解疾病的抗風濕生物製藥，在控制症狀、減輕發炎和預防關節損傷方面發揮重要作用。市場分為藥品（化學合成的小分子藥物）和生物製劑（使用活生物體或基因工程細胞製造的生技藥品），提供多樣化的治療選擇。

成長動力

抗風濕藥物市場的主要驅動力是風濕病患病率的上升，而全球人口老化則加劇了這一趨勢。與老齡化相關的關節軟骨劣化會導致疼痛、僵硬和活動能力下降，通常需要抗風濕藥物和關節重建等治療。根據世界衛生組織 (WHO) 的數據，類風濕性關節炎影響全球超過 2,300 萬人，女性罹患此病的可能性是男性的三倍。世界銀行強調，老化是風濕病患病率上升的一個主要因素，推動了對有效治療方法的需求。這種人口結構的變化凸顯了對藥物的需求，以控制症狀並改善 RA 和其他自體免疫疾病（如狼瘡）患者的生活品質，這些疾病會影響多個器官並引起廣泛的發炎。

市場範圍及應用

抗風濕藥物市場因其在治療類風濕性關節炎（RA）和乾癬性關節炎等自體免疫疾病中的作用而迅速擴張。這些藥物透過消炎、止痛和減緩關節損傷的進展來改善患者的預後。除了類風濕性關節炎之外，抗風濕藥物在治療紅斑性狼瘡方面也扮演重要角色。狼瘡是一種免疫系統攻擊健康細胞，導致關節、腎臟、心臟和肺部發炎的疾病。這些藥物適用於多種自體免疫疾病，既可以緩解症狀，又可以進行長期疾病管理，這推動了市場的成長。

地理視角

從區域來看，市場細分為北美、南美、歐洲、中東和非洲以及亞太地區，其中北美，尤其是美國，預計將佔據相當大的佔有率。美國市場的成長主要受到久坐不動、肥胖和不健康的生活習慣等因素的影響，導致關節炎盛行率不斷上升。美國疾病管制與預防中心預測，到2030年，將有7,200萬美國成年人被醫生診斷為關節炎，這將顯著增加疾病負擔，並增加對抗風濕藥物的需求。

技術創新與監管發展

最近的進展包括美國食品藥物管理局於 2023 年Janus核准Janus激酶抑制劑，這是一類新型 DMARD，旨在減緩 RA 患者關節損傷的進展。此類創新凸顯了該行業在開發標靶治療的持續努力，進一步推動了市場成長。

摘要，受人口老化、風濕病患病率上升以及抗風濕藥物（DMARDs）和生物製藥等創新療法的推動，抗風濕藥物市場預計將持續擴張。北美，尤其是美國，由於關節炎患者數量的增加和產品開發的強勁，將繼續成為主要的成長地區。

本報告的主要優點

深刻分析：獲得深入的市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採用的策略策略，並了解正確策略的市場滲透潛力。
市場促進因素和未來趨勢：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
可行的建議：利用洞察力來提供策略決策，在動態環境中開闢新的業務流和收益。
受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業來說，都是有益且具有成本效益的。

它有什麼用途？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開發、競爭影響

分析範圍

歷史資料（2022-2024）和預測資料（2025-2030）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按部門和地區（國家）分類的收益成長和預測分析
公司概況（策略、產品、財務資訊、主要趨勢等）

介紹
北美洲
- 依疾病類型
- 按藥品類別
- 按銷售管道
- 按國家
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 依疾病類型
- 按藥品類別
- 按銷售管道
- 按國家
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 依疾病類型
- 按藥品類別
- 按銷售管道
- 按國家
  - 英國
  - 德國
  - 法國
  - 西班牙
  - 其他
中東和非洲
- 依疾病類型
- 按藥品類別
- 按銷售管道
- 按國家
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 其他
亞太地區
- 依疾病類型
- 按藥品類別
- 按銷售管道
- 按國家
  - 中國
  - 日本
  - 印度
  - 韓國
  - 台灣
  - 其他

第9章競爭格局及分析

主要企業和策略分析
市場佔有率分析
企業合併、協議、商業合作
競爭對手儀表板

第10章：公司簡介

AbbVie Inc.
Pfizer Inc.
Johnson & Johnson
Amgen Inc.
Novartis AG
Eli Lilly and Company
Bristol Myers Squibb
Merck & Co., Inc.
Roche Holding AG
GlaxoSmithKline plc

第11章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要利益
分析方法
簡稱

簡介目錄

Product Code: KSI061613477

The Global Anti-Rheumatic Drug Market is expected to grow from USD 74.444 billion in 2025 to USD 84.200 billion in 2030, at a CAGR of 2.49%.

The global anti-rheumatic drug market is experiencing significant growth, driven by the rising prevalence of rheumatic diseases, particularly rheumatoid arthritis (RA), and an aging population. These chronic conditions, including RA, psoriatic arthritis, lupus, and osteoarthritis, cause inflammation, pain, and stiffness in joints, muscles, and bones, severely impacting patients' quality of life. Anti-rheumatic drugs, encompassing nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents, are critical in managing symptoms, reducing inflammation, and preventing joint damage. The market is segmented into pharmaceuticals (chemically synthesized small-molecule drugs) and biopharmaceuticals (biologics produced using living organisms or genetically engineered cells), offering diverse treatment options.

Growth Drivers

The primary driver of the anti-rheumatic drug market is the increasing prevalence of rheumatic diseases, exacerbated by an aging global population. As people age, joint cartilage deteriorates, leading to pain, stiffness, and reduced mobility, often necessitating treatments like anti-rheumatic drugs or joint replacement surgery. According to the World Health Organization, rheumatoid arthritis affects over 23 million people worldwide, with women three times more likely to develop it than men. The World Bank highlights the growing aging population as a key factor increasing the incidence of rheumatic disorders, thereby driving demand for effective therapies. This demographic shift underscores the need for drugs that manage symptoms and improve quality of life for patients with RA and other autoimmune diseases like lupus, which affects multiple organs and causes widespread inflammation.

Market Scope and Applications

The anti-rheumatic drug market is expanding rapidly due to its role in treating autoimmune conditions such as RA and psoriatic arthritis. These drugs reduce inflammation, alleviate pain, and slow joint damage progression, enhancing patient outcomes. Beyond RA, anti-rheumatic drugs are vital for managing lupus, where the immune system attacks healthy cells, leading to inflammation in joints, kidneys, heart, and lungs. The versatility of these drugs across various autoimmune diseases fuels market growth, as they address both symptom relief and long-term disease management.

Geographical Outlook

Geographically, the market is divided into North America, South America, Europe, the Middle East and Africa, and Asia Pacific, with North America, particularly the United States, expected to hold a significant share. The U.S. market is driven by rising arthritis prevalence, attributed to factors like sedentary lifestyles, obesity, and poor health habits. The Centers for Disease Control and Prevention projects that by 2030, 72 million U.S. adults will have doctor-diagnosed arthritis, reflecting a significant increase in disease burden and demand for anti-rheumatic drugs.

Innovations and Regulatory Developments

Recent advancements include the U.S. Food and Drug Administration's approval of Janus Kinase Inhibitors in January 2023, a new class of DMARDs designed to slow joint damage progression in RA patients. Such innovations highlight ongoing industry efforts to develop targeted therapies, further propelling market growth.

In summary, the anti-rheumatic drug market is poised for continued expansion, driven by an aging population, rising rheumatic disease prevalence, and innovative treatments like DMARDs and biologics. North America, particularly the U.S., remains a key growth region due to increasing arthritis cases and robust product development.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2020 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Type Of Disease

Rheumatoid Arthritis
Osteoarthritis
Psoriatic Arthritis
Gout
Lupus
Ankylosing Spondylitis
Others

By Drug Class

Disease-modifying Anti-Rheumatic Drugs (DMARDs)
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
JAK inhibitor
Others

By Sales Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Geography

North America
South America
Europe
Middle East and Africa
Asia Pacific

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY TYPE OF DISEASE

5.1. Introduction
5.2. Rheumatoid Arthritis
5.3. Osteoarthritis
5.4. Psoriatic Arthritis
5.5. Gout
5.6. Lupus
5.7. Ankylosing Spondylitis
5.8. Others

6. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY DRUG CLASS

6.1. Introduction
6.2. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.4. Corticosteroids
6.5. JAK inhibitor
6.6. Others

7. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY SALES CHANNEL

7.1. Introduction
7.2. Hospital Pharmacies
7.3. Retail Pharmacies
7.4. Online Pharmacies

8. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. By Type of Disease
- 8.2.2. By Drug Class
- 8.2.3. By Sales Channel
- 8.2.4. By Country
  - 8.2.4.1. USA
  - 8.2.4.2. Canada
  - 8.2.4.3. Mexico
8.3. South America
- 8.3.1. By Type of Disease
- 8.3.2. By Drug Class
- 8.3.3. By Sales Channel
- 8.3.4. By Country
  - 8.3.4.1. Brazil
  - 8.3.4.2. Argentina
  - 8.3.4.3. Others
8.4. Europe
- 8.4.1. By Type of Disease
- 8.4.2. By Drug Class
- 8.4.3. By Sales Channel
- 8.4.4. By Country
  - 8.4.4.1. United Kingdom
  - 8.4.4.2. Germany
  - 8.4.4.3. France
  - 8.4.4.4. Spain
  - 8.4.4.5. Others
8.5. Middle East and Africa
- 8.5.1. By Type of Disease
- 8.5.2. By Drug Class
- 8.5.3. By Sales Channel
- 8.5.4. By Country
  - 8.5.4.1. Saudi Arabia
  - 8.5.4.2. UAE
  - 8.5.4.3. Others
8.6. Asia Pacific
- 8.6.1. By Type of Disease
- 8.6.2. By Drug Class
- 8.6.3. By Sales Channel
- 8.6.4. By Country
  - 8.6.4.1. China
  - 8.6.4.2. Japan
  - 8.6.4.3. India
  - 8.6.4.4. South Korea
  - 8.6.4.5. Taiwan
  - 8.6.4.6. Others